400 related articles for article (PubMed ID: 22954454)
1. Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy.
Brindley DN; Lin FT; Tigyi GJ
Biochim Biophys Acta; 2013 Jan; 1831(1):74-85. PubMed ID: 22954454
[TBL] [Abstract][Full Text] [Related]
2. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance.
Samadi N; Bekele R; Capatos D; Venkatraman G; Sariahmetoglu M; Brindley DN
Biochimie; 2011 Jan; 93(1):61-70. PubMed ID: 20709140
[TBL] [Abstract][Full Text] [Related]
3. Role of the autotaxin-lysophosphatidate axis in the development of resistance to cancer therapy.
Tang X; Benesch MGK; Brindley DN
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Aug; 1865(8):158716. PubMed ID: 32305571
[TBL] [Abstract][Full Text] [Related]
4. Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.
Tigyi GJ; Yue J; Norman DD; Szabo E; Balogh A; Balazs L; Zhao G; Lee SC
Adv Biol Regul; 2019 Jan; 71():183-193. PubMed ID: 30243984
[TBL] [Abstract][Full Text] [Related]
5. Signalling by lysophosphatidate and its health implications.
Hemmings DG; Brindley DN
Essays Biochem; 2020 Sep; 64(3):547-563. PubMed ID: 32451553
[TBL] [Abstract][Full Text] [Related]
6. Autotaxin and LPA receptor signaling in cancer.
Houben AJ; Moolenaar WH
Cancer Metastasis Rev; 2011 Dec; 30(3-4):557-65. PubMed ID: 22002750
[TBL] [Abstract][Full Text] [Related]
7. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.
Gotoh M; Fujiwara Y; Yue J; Liu J; Lee S; Fells J; Uchiyama A; Murakami-Murofushi K; Kennel S; Wall J; Patil R; Gupte R; Balazs L; Miller DD; Tigyi GJ
Biochem Soc Trans; 2012 Feb; 40(1):31-6. PubMed ID: 22260662
[TBL] [Abstract][Full Text] [Related]
8. Dexamethasone decreases the autotaxin-lysophosphatidate-inflammatory axis in adipose tissue: implications for the metabolic syndrome and breast cancer.
Meng G; Tang X; Yang Z; Zhao Y; Curtis JM; McMullen TPW; Brindley DN
FASEB J; 2019 Feb; 33(2):1899-1910. PubMed ID: 30192654
[TBL] [Abstract][Full Text] [Related]
9. Biological roles of lysophosphatidic acid signaling through its production by autotaxin.
Okudaira S; Yukiura H; Aoki J
Biochimie; 2010 Jun; 92(6):698-706. PubMed ID: 20417246
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrest.
Samadi N; Bekele RT; Goping IS; Schang LM; Brindley DN
PLoS One; 2011; 6(5):e20608. PubMed ID: 21647386
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of autotaxin/lysophospholipase d inhibitors.
Federico L; Pamuklar Z; Smyth SS; Morris AJ
Curr Drug Targets; 2008 Aug; 9(8):698-708. PubMed ID: 18691016
[TBL] [Abstract][Full Text] [Related]
12. The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer.
Quan M; Cui JJ; Feng X; Huang Q
Tumour Biol; 2017 Mar; 39(3):1010428317694544. PubMed ID: 28347252
[TBL] [Abstract][Full Text] [Related]
13. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
Tabuchi S
Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
[TBL] [Abstract][Full Text] [Related]
14. Role of Adipose Tissue-Derived Autotaxin, Lysophosphatidate Signaling, and Inflammation in the Progression and Treatment of Breast Cancer.
Brindley DN; Tang X; Meng G; Benesch MGK
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824846
[TBL] [Abstract][Full Text] [Related]
15. Lysophosphatidic acid (LPA) receptor-mediated signaling and cellular responses to anticancer drugs and radiation of cancer cells.
Ikeda H; Takai M; Tsujiuchi T
Adv Biol Regul; 2024 May; 92():101029. PubMed ID: 38377635
[TBL] [Abstract][Full Text] [Related]
16. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.
Teo K; Brunton VG
Biochem J; 2014 Oct; 463(1):157-65. PubMed ID: 25195735
[TBL] [Abstract][Full Text] [Related]
17. Autotaxin-LPA-LPP3 Axis in Energy Metabolism and Metabolic Disease.
Jose A; Kienesberger PC
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502491
[TBL] [Abstract][Full Text] [Related]
18. Autotaxin-LPA axis regulates hMSC migration by adherent junction disruption and cytoskeletal rearrangement via LPAR1/3-dependent PKC/GSK3β/β-catenin and PKC/Rho GTPase pathways.
Ryu JM; Han HJ
Stem Cells; 2015 Mar; 33(3):819-32. PubMed ID: 25376707
[TBL] [Abstract][Full Text] [Related]
19. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
Seo EJ; Kwon YW; Jang IH; Kim DK; Lee SI; Choi EJ; Kim KH; Suh DS; Lee JH; Choi KU; Lee JW; Mok HJ; Kim KP; Matsumoto H; Aoki J; Kim JH
Stem Cells; 2016 Mar; 34(3):551-64. PubMed ID: 26800320
[TBL] [Abstract][Full Text] [Related]
20. Production of extracellular lysophosphatidic acid in the regulation of adipocyte functions and liver fibrosis.
Yang F; Chen GX
World J Gastroenterol; 2018 Sep; 24(36):4132-4151. PubMed ID: 30271079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
